On October 14, 2025, Microbot Medical Inc. announced a partnership with a U.S. logistics company for the commercialization of its FDA-cleared LIBERTY® Endovascular Robotic System, with a market release planned for Q4 2025 and a broader launch at the April 2026 conference.